Targeted Next-Generation Sequencing in Patients with Suggestive X-Linked Intellectual Disability.


Journal

Genes
ISSN: 2073-4425
Titre abrégé: Genes (Basel)
Pays: Switzerland
ID NLM: 101551097

Informations de publication

Date de publication:
02 01 2020
Historique:
received: 03 12 2019
revised: 19 12 2019
accepted: 30 12 2019
entrez: 8 1 2020
pubmed: 8 1 2020
medline: 24 6 2020
Statut: epublish

Résumé

X-linked intellectual disability (XLID) is known to contribute up to 10% of intellectual disability (ID) in males and could explain the increased ratio of affected males observed in patients with ID. Over the past decade, next-generation sequencing has clearly stimulated the gene discovery process and has become part of the diagnostic procedure. We have performed targeted next-generation sequencing of 82 XLID genes on 61 non-related male patients with suggestive non-syndromic XLID. These patients were initially referred to the molecular genetics laboratory to exclude Fragile X Syndrome. The cohort includes 47 male patients with suggestive X-linked family history of ID meaning that they had half-brothers or maternal cousins or uncles affected; and 14 male patients with ID and affected brothers whose mothers show skewed X-inactivation. Sequencing data analysis identified 17 candidate variants in 16 patients. Seven families could be re-contacted and variant segregation analysis of the respective eight candidate variants was performed:

Identifiants

pubmed: 31906484
pii: genes11010051
doi: 10.3390/genes11010051
pmc: PMC7017351
pii:
doi:

Substances chimiques

Guanine Nucleotide Exchange Factors 0
IQSEC2 protein, human 0
MED12 protein, human 0
Mediator Complex 0
Nerve Tissue Proteins 0
Plasma Membrane Neurotransmitter Transport Proteins 0
SLC6A8 protein, human 0
SLC9A6 protein, human 0
Sodium-Hydrogen Exchangers 0
Transcription Factors 0
Monoamine Oxidase EC 1.4.3.4
monoamine oxidase A, human EC 1.4.3.4.

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Déclaration de conflit d'intérêts

The authors declare no conflict of interest.

Références

Clin Genet. 2018 Nov;94(5):450-456
pubmed: 30006928
Clin Genet. 2020 Mar;97(3):418-425
pubmed: 31705537
Nat Genet. 2010 Dec;42(12):1109-12
pubmed: 21076407
Am J Hum Genet. 2008 Apr;82(4):1003-10
pubmed: 18342287
Cytogenet Genome Res. 2002;99(1-4):265-75
pubmed: 12900574
Am J Hum Genet. 2018 Jan 4;102(1):175-187
pubmed: 29276005
Am J Hum Genet. 2002 Jul;71(1):168-73
pubmed: 12068376
Nature. 2015 Mar 12;519(7542):223-8
pubmed: 25533962
Front Genet. 2019 Oct 31;10:1074
pubmed: 31737052
Am J Med Genet A. 2016 Aug;170(8):2103-10
pubmed: 27256868
Mol Psychiatry. 2019 Jul;24(7):1027-1039
pubmed: 29302074
Small GTPases. 2010 Sep;1(2):98-103
pubmed: 21686261
Curr Opin Genet Dev. 2006 Jun;16(3):260-9
pubmed: 16647850
Am J Hum Genet. 1980 Sep;32(5):714-22
pubmed: 6107045
Pediatr Res. 2008 Aug;64(2):218-22
pubmed: 18391841
J Med Genet. 2014 Nov;51(11):724-36
pubmed: 25167861
Hum Genet. 2006 Jul;119(6):604-10
pubmed: 16738945
Int J Mol Sci. 2019 Jun 21;20(12):
pubmed: 31234416
Am J Med Genet. 1994 Jul 15;51(4):586-90
pubmed: 7943044
Mol Psychiatry. 2016 Jan;21(1):133-48
pubmed: 25644381
Eur J Hum Genet. 2015 Nov;23(11):1513-8
pubmed: 25649377
Am J Hum Genet. 2012 Apr 6;90(4):579-90
pubmed: 22482801
Nat Rev Genet. 2005 Jan;6(1):46-57
pubmed: 15630421
Front Genet. 2019 Jun 26;10:578
pubmed: 31316545
PLoS One. 2015 Feb 13;10(2):e0116454
pubmed: 25679214
Am J Hum Genet. 2013 Mar 7;92(3):401-6
pubmed: 23395478
Orphanet J Rare Dis. 2014 Apr 11;9:49
pubmed: 24721225
Genet Med. 2016 Jul;18(7):696-704
pubmed: 26633542
Mol Psychiatry. 2010 Jul;15(7):767-76
pubmed: 19238151
Sci Rep. 2017 Nov 8;7(1):15050
pubmed: 29118367
Genet Med. 2001 Sep-Oct;3(5):359-71
pubmed: 11545690
Am J Hum Genet. 2001 Jun;68(6):1497-500
pubmed: 11326334
N Engl J Med. 2017 Jan 5;376(1):21-31
pubmed: 27959697
Res Dev Disabil. 2011 Mar-Apr;32(2):419-36
pubmed: 21236634
Nat Rev Genet. 2016 Jan;17(1):9-18
pubmed: 26503795
Am J Hum Genet. 2017 Feb 2;100(2):267-280
pubmed: 28132688
Nat Genet. 2009 May;41(5):535-43
pubmed: 19377476
BMJ Open. 2016 Apr 29;6(4):e009537
pubmed: 27130160
Clin Genet. 2007 Jul;72(1):19-22
pubmed: 17594395
Hum Mutat. 2019 Jan;40(1):5-24
pubmed: 30328660
J Neurosci. 2012 Aug 22;32(34):11716-26
pubmed: 22915114
Genet Med. 2015 May;17(5):405-24
pubmed: 25741868
Front Mol Neurosci. 2016 Jan 11;8:85
pubmed: 26793055
Clin Genet. 2007 Aug;72(2):145-9
pubmed: 17661819
J Comput Biol. 1997 Fall;4(3):311-23
pubmed: 9278062
J Med Genet. 2007 Jul;44(7):472-7
pubmed: 17369503
J Med Genet. 2005 Oct;42(10):780-6
pubmed: 16199551
Am J Hum Genet. 2008 Feb;82(2):432-43
pubmed: 18252223
Nat Methods. 2014 Apr;11(4):361-2
pubmed: 24681721
Nat Genet. 2014 Mar;46(3):310-5
pubmed: 24487276
Dev Disabil Res Rev. 2009;15(4):361-8
pubmed: 20014364
Ann Neurol. 2014 Oct;76(4):581-93
pubmed: 25044251
Nat Methods. 2010 Apr;7(4):248-9
pubmed: 20354512
Am J Med Genet A. 2018 Jun;176(6):1375-1388
pubmed: 29696803
Hum Genet. 2009 Sep;126(3):363-73
pubmed: 19396465
Nucleic Acids Res. 2009 May;37(9):e67
pubmed: 19339519
Eur J Hum Genet. 2018 Jan;26(1):64-74
pubmed: 29180823
eNeuro. 2019 Dec 4;6(6):
pubmed: 31676550
Small GTPases. 2020 Jan;11(1):1-7
pubmed: 29363391
Am J Hum Genet. 1992 Dec;51(6):1229-39
pubmed: 1281384
Hum Mol Genet. 2011 Jun 15;20(12):2297-307
pubmed: 21441247
Am J Med Genet. 1999 Jul 30;85(3):216-20
pubmed: 10398231
Nat Genet. 2010 Jun;42(6):486-8
pubmed: 20473311
Eur J Paediatr Neurol. 2017 May;21(3):475-484
pubmed: 28027854
Clin Chim Acta. 2001 Jun;308(1-2):173-8
pubmed: 11412830
J Med Genet. 2004 Mar;41(3):183-6
pubmed: 14985377
Nat Genet. 2007 Apr;39(4):451-3
pubmed: 17334363
Neurobiol Dis. 2019 Jan;121:187-204
pubmed: 30296617
Front Mol Neurosci. 2019 Feb 20;12:43
pubmed: 30842726
Nat Protoc. 2009;4(7):1073-81
pubmed: 19561590

Auteurs

Nekane Ibarluzea (N)

Biocruces Bizkaia Health Research Institute, 48903 Barakaldo, Spain.
Spanish Consortium for Research on Rare Diseases (CIBERER), 28029 Madrid, Spain.

Ana Belén de la Hoz (AB)

Biocruces Bizkaia Health Research Institute, 48903 Barakaldo, Spain.
Spanish Consortium for Research on Rare Diseases (CIBERER), 28029 Madrid, Spain.

Olatz Villate (O)

Biocruces Bizkaia Health Research Institute, 48903 Barakaldo, Spain.
Spanish Consortium for Research on Rare Diseases (CIBERER), 28029 Madrid, Spain.
Genetics Service, Cruces University Hospital, Osakidetza Basque Health Service, 48903 Barakaldo, Spain.

Isabel Llano (I)

Biocruces Bizkaia Health Research Institute, 48903 Barakaldo, Spain.
Spanish Consortium for Research on Rare Diseases (CIBERER), 28029 Madrid, Spain.
Genetics Service, Cruces University Hospital, Osakidetza Basque Health Service, 48903 Barakaldo, Spain.

Intzane Ocio (I)

Department of Paediatric Neurology, Araba University Hospital, Osakidetza Basque Health Service, 01009 Gasteiz, Spain.

Itxaso Martí (I)

Department of Paediatric Neurology, Donostia University Hospital, Osakidetza Basque Health Service, 20014 Donostia, Spain.

Miriam Guitart (M)

Genetics Laboratory, Paediatric Unit, Parc Taulí Hospital Universitari, Institut d'Investigació i Innovació Parc Taulí I3PT, Universitat Autònoma de Barcelona, 08208 Sabadell, Spain.

Elisabeth Gabau (E)

Genetics Laboratory, Paediatric Unit, Parc Taulí Hospital Universitari, Institut d'Investigació i Innovació Parc Taulí I3PT, Universitat Autònoma de Barcelona, 08208 Sabadell, Spain.

Fernando Andrade (F)

Biocruces Bizkaia Health Research Institute, 48903 Barakaldo, Spain.
Spanish Consortium for Research on Rare Diseases (CIBERER), 28029 Madrid, Spain.

Blanca Gener (B)

Biocruces Bizkaia Health Research Institute, 48903 Barakaldo, Spain.
Spanish Consortium for Research on Rare Diseases (CIBERER), 28029 Madrid, Spain.
Genetics Service, Cruces University Hospital, Osakidetza Basque Health Service, 48903 Barakaldo, Spain.

María-Isabel Tejada (MI)

Biocruces Bizkaia Health Research Institute, 48903 Barakaldo, Spain.
Spanish Consortium for Research on Rare Diseases (CIBERER), 28029 Madrid, Spain.
Genetics Service, Cruces University Hospital, Osakidetza Basque Health Service, 48903 Barakaldo, Spain.

Articles similaires

Genome, Chloroplast Phylogeny Genetic Markers Base Composition High-Throughput Nucleotide Sequencing

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C

Classifications MeSH